AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10519499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prerandomized consent to experimental treatment
Number of subjects: 770
Study 10519499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prerandomized consent to standard treatment
Number of subjects: 770
Study 10519499 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sided physician-modified informed consent
Number of subjects: 770
Study 10519499 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sided patient-modified informed consent
Number of subjects: 770
Study 10519499 — intervention group
Group type: COMPARATOR
Intervention: Control group (one-sided informed consent)
Number of subjects: 770
Study 8537265 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g tds iv
Number of subjects: 221
Study 8537265 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g tds iv
Number of subjects: 221
Study 1958005 — intervention group
Group type: EXPERIMENTAL
Intervention: Phadebas radioallergosorbent test (PhRAST)
Number of subjects: 128
Study 1958005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacia CAP System (CAP)
Number of subjects: 128
Study 1958005 — intervention group
Group type: EXPERIMENTAL
Intervention: modified RAST (mRAST)
Number of subjects: 128
Study 1958005 — intervention group
Group type: EXPERIMENTAL
Intervention: modified RAST (mRAST) with threshold raised to class 2
Number of subjects: 128
Study 29610221 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM insertion technique
Number of subjects: 41
Study 29610221 — intervention group
Group type: COMPARATOR
Intervention: Inverted ILM flap technique
Number of subjects: 41
Study 27916242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin and methylcobalamin combination (PG‐B12)
Number of subjects: 100
Study 27916242 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium (DP)
Number of subjects: 100
Study 25416241 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days' voice rest
Number of subjects: 31
Study 25416241 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days' voice rest
Number of subjects: 31
Study 23890528 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I trimming technique (1-cm incision, glandular and subcutaneous tissue removal using scissors)
Number of subjects: 150
Study 23890528 — intervention group
Group type: COMPARATOR
Intervention: Type II trimming technique (4-5-cm incision, trimming under direct vision)
Number of subjects: 150
Study 23013746 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with 20 mg/kg alglucosidase alfa biweekly
Number of subjects: 69
Study 20128370 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 295
Study 20128370 — intervention group
Group type: COMPARATOR
Intervention: Drug Eluting Stent (DES)
Number of subjects: 295
Study 17541390 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg (dose titrated to 300 mg if needed)
Number of subjects: 183
Study 17541390 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg (dose titrated to 40 mg if needed)
Number of subjects: 183
Study 15361558 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART stent
Number of subjects: 203
Study 15361558 — intervention group
Group type: COMPARATOR
Intervention: Wallstent
Number of subjects: 203
Study 11302613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 0
Study 11302613 — intervention group
Group type: COMPARATOR
Intervention: Control site (no fibrin sealant)
Number of subjects: 0
Study 9724486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy aimed at near normoglycemia
Number of subjects: 0
Study 7979840 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (50 to 300 mg three times per day)
Number of subjects: 212
Study 7979840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 2692090 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin A
Number of subjects: 7
Study 825076 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) stimulation
Number of subjects: 0
Study 825076 — intervention group
Group type: EXPERIMENTAL
Intervention: Three intravenous doses of 600 mug of TRH over 15 days
Number of subjects: 0
Study 825076 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated challenges with TRH
Number of subjects: 0
Study 30517975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Number of subjects: 36
Study 30517975 — intervention group
Group type: COMPARATOR
Intervention: PTFE sutures
Number of subjects: 36
Study 27791532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational emotive behaviour therapy (REBT)
Number of subjects: 62
Study 27791532 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional placebo (ATP)
Number of subjects: 62
Study 27791532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sessions)
Number of subjects: 62
Study 25726502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.25 mg/kg (maximum 25 mg)
Number of subjects: 104
Study 25726502 — intervention group
Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg (maximum 90 mg)
Number of subjects: 104
Study 25726502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 104
Study 25726502 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 104
Study 23904396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 109
Study 23904396 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 109
Study 23904396 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT volume increase
Number of subjects: 109
Study 21481381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystectomy
Number of subjects: 48
Study 21481381 — intervention group
Group type: COMPARATOR
Intervention: Coagulation
Number of subjects: 48
Study 19807152 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthone-rich mangosteen liquid (59 mL)
Number of subjects: 0
Study 16731547 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate and testosterone undecanoate injections
Number of subjects: 90
Study 16731547 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 90
Study 15301643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 90
Study 15301643 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 90
Study 15301643 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 90
Study 10910852 — intervention group
Group type: EXPERIMENTAL
Intervention: IV verapamil 2.5 mg and morphine 5 mg added to lidocaine solution (Group 3)
Number of subjects: 75
Study 10910852 — intervention group
Group type: EXPERIMENTAL
Intervention: IV morphine 5 mg and verapamil 2.5 mg added to lidocaine solution (Group 4)
Number of subjects: 75
Study 10910852 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 2.5 mg and morphine 5 mg added to lidocaine solution (Group 5)
Number of subjects: 75
Study 10910852 — intervention group
Group type: COMPARATOR
Intervention: IV saline (Group 1)
Number of subjects: 75
Study 9071903 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (160 mg daily)
Number of subjects: 64
Study 9071903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 8418770 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy
Number of subjects: 0
Study 3738977 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement of the doctor's advice by a nurse
Number of subjects: 150
Study 3738977 — intervention group
Group type: EXPERIMENTAL
Intervention: Written instructions to the patients
Number of subjects: 150
Study 3738977 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 150
Study 30509862 — intervention group
Group type: EXPERIMENTAL
Intervention: Uni HIIT program (n=26)
Number of subjects: 53
Study 30509862 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n=27)
Number of subjects: 53
Study 29330977 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-Assisted Learning (PAL)
Number of subjects: 120
Study 29330977 — intervention group
Group type: COMPARATOR
Intervention: Expert-Assisted Learning (EAL)
Number of subjects: 120
Study 29330977 — intervention group
Group type: COMPARATOR
Intervention: Pre-test
Number of subjects: 120
Study 25882376 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy with stent retriever plus intravenous t-PA
Number of subjects: 196
Study 25882376 — intervention group
Group type: COMPARATOR
Intervention: Intravenous t-PA alone (control group)
Number of subjects: 196
Study 24195220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at Jiaji points
Number of subjects: 60
Study 24195220 — intervention group
Group type: COMPARATOR
Intervention: Medication group (pinaverium bromide tablet)
Number of subjects: 60
Study 21509914 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive-Compulsive Scale Symptom Checklist (YBOCS-SC)
Number of subjects: 201
Study 21509914 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis including mental compulsions and reassurance-seeking
Number of subjects: 201
Study 17940545 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy + probiotic (yoghurt)
Number of subjects: 36
Study 17940545 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy + prebiotic (resistant starch)
Number of subjects: 36
Study 17940545 — intervention group
Group type: COMPARATOR
Intervention: Control soy diet
Number of subjects: 36
Study 16322964 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide excision plus asymmetric modified Limberg flap (Group 2)
Number of subjects: 68
Study 16322964 — intervention group
Group type: COMPARATOR
Intervention: Wide excision plus classic Limberg flap (Group 1)
Number of subjects: 68
Study 15526809 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 15
Study 15526809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15526809 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS inhalation
Number of subjects: 15
Study 15526809 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 15
Study 11295905 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 46
Study 9203722 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent type 1 oral poliovirus vaccine (OPV) at 6 months and trivalent OPV at 7 and 9 months (Group 1)
Number of subjects: 547
Study 9203722 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV at birth and 3 doses of OPV and inactivated poliovirus vaccine (IPV) (Group 2)
Number of subjects: 547
Study 9203722 — intervention group
Group type: COMPARATOR
Intervention: Placebo at birth and 3 doses of IPV (Group 3)
Number of subjects: 547
Study 9203722 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent type 1 OPV following 3 IPV doses (Group 2)
Number of subjects: 547
Study 9203722 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent OPV (Group 1)
Number of subjects: 547
Study 9203722 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 547
Study 7703709 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation Group intervention to reduce waiting time for treatment
Number of subjects: 0
Study 3237852 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon inflated with 400 ml or more of water
Number of subjects: 8
Study 3237852 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon capacity measurement
Number of subjects: 8
Study 3237852 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of stomach capacity to spontaneous food intake
Number of subjects: 8
Study 3237852 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of stomach capacity to balloon volume needed to suppress 50% of spontaneous intake
Number of subjects: 8
Study 31206595 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated open application test (ROAT) with fragrance mix I
Number of subjects: 109
Study 31206595 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm indicating positive contact allergy
Number of subjects: 109
Study 31206595 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch test reactivity to fragrance mix I
Number of subjects: 109
Study 30014535 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-oriented social group work intervention (9 group sessions focusing on capacity building and increasing individual competences, environmental resources and opportunities)
Number of subjects: 60
Study 30014535 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 27052688 — intervention group
Group type: EXPERIMENTAL
Intervention: IV metoprolol (15 mg bolus)
Number of subjects: 218
Study 27052688 — intervention group
Group type: EXPERIMENTAL
Intervention: IV metoprolol (25 min before reperfusion)
Number of subjects: 218
Study 27052688 — intervention group
Group type: COMPARATOR
Intervention: Control (IV vehicle)
Number of subjects: 218
Study 24997587 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment every 6 months
Number of subjects: 186
Study 24997587 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray assessment every 6 months
Number of subjects: 186
Study 24997587 — intervention group
Group type: COMPARATOR
Intervention: Sham-intervention
Number of subjects: 186
Study 24997587 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 186
Study 22120766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 224
Study 22120766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 20100808 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-assisted pharmacist counseling
Number of subjects: 300
Study 20100808 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ plus 8 weeks of nicotine transdermal patch (EQ+)
Number of subjects: 300
Study 20100808 — intervention group
Group type: COMPARATOR
Intervention: Observation-only group (OBS)
Number of subjects: 300
Study 18448221 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-based sun protection intervention with UV photo and photoaging information
Number of subjects: 125
Study 18448221 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-based sun protection intervention with both injunctive and descriptive norms information
Number of subjects: 125
Study 18448221 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 125
Study 15741547 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucantime (20 mg of antimony [Sb]/kg/day intravenously for 20 days)
Number of subjects: 80
Study 15741547 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine (2 mg/kg every other day for seven injections)
Number of subjects: 80
Study 11838918 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention plus Booster session (BIB)
Number of subjects: 539
Study 11838918 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 539
Study 11838918 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 539
Study 9990361 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ ASM 981 (1.0%)
Number of subjects: 10
Study 9990361 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ ASM 981 (0.3%)
Number of subjects: 10
Study 9990361 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol-17-propionate (0.05%)
Number of subjects: 10
Study 9990361 — intervention group
Group type: COMPARATOR
Intervention: Ointment base (placebo)
Number of subjects: 10
Study 7996960 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppb sulphur dioxide
Number of subjects: 10
Study 7996960 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ppb nitrogen dioxide
Number of subjects: 10
Study 7996960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 200 ppb sulphur dioxide and 400 ppb nitrogen dioxide
Number of subjects: 10
Study 7996960 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 10
Study 3414518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 57
Study 3414518 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 57
Study 29859917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lithium (150-600 mg) targeting a blood level of 0.2-0.6 mmol/L
Number of subjects: 0
Study 29859917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27792869 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g transdermal testosterone gel (TT) daily for 12 months
Number of subjects: 29
Study 27792869 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg anastrozole (AI) daily for 12 months
Number of subjects: 29
Study 27792869 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 12 months
Number of subjects: 29
Study 22457097 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiac shock wave therapy (CSWT)
Number of subjects: 25
Study 22457097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 25
Study 20677024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilatation
Number of subjects: 150
Study 20677024 — intervention group
Group type: COMPARATOR
Intervention: Non-dilated group
Number of subjects: 150
Study 19583713 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole with lactobacilli (200 mg bid for acute infection followed by monthly single-day treatment)
Number of subjects: 150
Study 19583713 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole without lactobacilli (200 mg bid for acute infection followed by monthly single-day treatment)
Number of subjects: 150
Study 19583713 — intervention group
Group type: COMPARATOR
Intervention: Classic homeopathy (CH) treatment for 12 months
Number of subjects: 150
Study 16500299 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD placement
Number of subjects: 274
Study 16500299 — intervention group
Group type: COMPARATOR
Intervention: Control (no ICD placement)
Number of subjects: 274
Study 15014414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish, conventional adhesive
Number of subjects: 48
Study 15014414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish, self-etching primer system
Number of subjects: 48
Study 15014414 — intervention group
Group type: COMPARATOR
Intervention: No fluoride varnish, conventional adhesive
Number of subjects: 48
Study 15014414 — intervention group
Group type: COMPARATOR
Intervention: No fluoride varnish, self-etching primer system
Number of subjects: 48
Study 11223044 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal wire (stainless steel)
Number of subjects: 37
Study 11223044 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable polyester (5 Ethibond)
Number of subjects: 37
Study 9779696 — intervention group
Group type: EXPERIMENTAL
Intervention: CR oxycodone every 12 hours
Number of subjects: 164
Study 9779696 — intervention group
Group type: COMPARATOR
Intervention: IR oxycodone four times daily
Number of subjects: 164
Study 8162750 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation with pressure support ventilation (PSV)
Number of subjects: 19
Study 8162750 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV) alone
Number of subjects: 19
Study 2735329 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 200 mg three times daily and 400 mg at night
Number of subjects: 46
Study 2735329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times daily followed by 1 g twice daily after healing
Number of subjects: 46
Study 31810793 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmunoCard STAT! HpSA HD (rapid test)
Number of subjects: 264
Study 31810793 — intervention group
Group type: COMPARATOR
Intervention: Premier Platinum HpSA PLUS (EIA test)
Number of subjects: 264
Study 31091579 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 100
Study 31091579 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 28658082 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-Minute Workout (7Min)
Number of subjects: 14
Study 28658082 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 14
Study 28658082 — intervention group
Group type: COMPARATOR
Intervention: HIIE
Number of subjects: 14
Study 25528496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilaralisib 600mg capsules or 400mg tablets once daily
Number of subjects: 67
Study 23202438 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized, standardized motor training (3 months)
Number of subjects: 91
Study 23202438 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity motor placebo activity (control)
Number of subjects: 91
Study 22099130 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 60
Study 22099130 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 60
Study 19751081 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation condition (writing two essays on important values over a 2-week period prior to exam)
Number of subjects: 0
Study 19751081 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 15679791 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 24
Study 15679791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 24
Study 15679791 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride
Number of subjects: 24
Study 15679791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12677739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus ultrasound
Number of subjects: 150
Study 12677739 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination and symptoms
Number of subjects: 150
Study 12677739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus ultrasound as a diagnostic criterion
Number of subjects: 150
Study 12677739 — intervention group
Group type: COMPARATOR
Intervention: Sinus radiography
Number of subjects: 150